Erythromycin derivatives

Claim 2

A compound of the formula I or pharmaceutically acceptable salts or prodrugs thereof, wherein: R is C 1 -C 10 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, or C 3 -C 10 cycloalkyl, wherein one or two carbons of said alkyl, cycloalkyl, alkenyl, alkynyl are optionally replaced by one or more heteroatoms selected from O, S and N, and are optionally substituted by one or more substituents selected from the group (hereinafter also referred to as “Group A”) consisting of: nitro; N 3 ; CN; C 1 -C 10 alkoxy; C 1 -C 10 alkanoyl; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 10 cycloalkyl; 4 to 10 heterocyclic; —C(O)R 10 ; —C(O)OR 10 ; —NR 10 R 11 ; —NHC(O)R 10 ; —NHC(O)NR 10 R 11 ; —S(O) n , wherein n is 0, 1, or 2; —SO 2 R 10 ; —SO 2 NR 10 R 11 ; wherein each R 1 , R 2 , R 3 1 , and R 4 is independently selected from the group consisting of H, C 1 -C 12 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, (CR 8 R 9 ) m Z, m is an integer from 0 to 6; wherein one or two carbons of said alkyl, alkenyl, alkynyl are optionally replaced by a heteroatom selected from the group consisting of O, S and N, and are optionally substituted by one or more substituents selected from Group A; or R 2 and R 3 , together with the carbon to which they are attached, form a 3-10 membered ring; the ring carbons are optionally substituted by one or more heteroatoms selected from the group consisting of O, S and N; R 5 is selected from the group consisting of C 1 -C 10 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, —CH 2 —CH═CH—Z, (CR 9 R 10 ) m Z; m is an integer from 1 to 6; wherein the alkyl, alkenyl and alkynyl can be substituted with one or more substituents selected from Group A; R 6 is H, —C(O)O(C 1 -C 18 ) alkyl or —C(O)(C 1 -C 18 ) alkyl, wherein one or more carbons of said alkyl may be replaced by a heteroatom selected from O, S and N; R 8 and R 9 are independently selected from the group consisting of H, halo, C 1 -C 6 alkyl; or R 8 and R 9 , together with the carbon to which they are attached, form a 3 to 10 membered cyclic or heterocyclic di-radical; each R 10 and R 11 is individually H or C 1 -C 12 alkyl, or aryl substituted C 1 -C 12 alkyl, or heteroaryl substituted C 1 -C 12 alkyl, wherein one or more carbons of either of said alkyl are optionally replaced by a heteroatom selected from O, S and N; each Z is independently a 4-10 membered heterocyclic or C 6 -C 10 aryl, wherein said heterocyclic and aryl groups are optionally substituted by one or more substituents selected from Group A; T is absent or selected from the group consisting of: —C(O)—, —C(O)—O—, —CH 2 —, —C(S)—S—, —C(O)—NR 10 —; —S(O) n —, where n is 0, 1, or 2, —S(O) n —O—, wherein n is 0, 1, or 2, —P(O)(OR 10 ) n —, n is 0, 1, or 2, and —S(O) 2 —NR 10 —, R t is selected from the group consisting of: C 1 -C 6 alkyl, C 3 -C 6 alkenyl, C 3 -C 12 cycloalkyl, aryl, heteroaryl, heterocycloalkyl, wherein said alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl groups are optionally substituted by one or more substituents selected from Group A.

Claim 3

A compound of formula 2 or pharmaceutically acceptable salts or prodrugs thereof, wherein: R is C 1 -C 10 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, or C 3 -C 10 cycloalkyl, wherein one or two carbons of said alkyl, cycloalkyl, alkenyl, alkynyl are optionally replaced by one or more heteroatoms selected from the group consisting of O, S and N, and are optionally substituted by one or more substituents selected from the group (hereinafter also referred to as “Group A”) consisting of: nitro; N 3 ; CN; C 1 -C 10 alkoxy; C 1 -C 10 alkanoyl; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 10 cycloalkyl; C 3 -C 10 heterocyclic; —C(O)R 10 ; —C(O)OR 10 ; —NR 10 R 11 ; —NHC(O)R 10 ; —NHC(O)NR 10 R 11 ; —S(O) n , wherein n is 0, 1, or 2; —SO 2 R 10 ; —SO 2 NR 10 R 11 ; R 1 and R 4 are independently selected from H, C 1 -C 12 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, (CR 8 R 9 ) m Z, m is an integer from 0 to 6; wherein one or two carbons of said alkyl, alkenyl, alkynyl are optionally replaced by a heteroatom selected from O, S and N, and are optionally substituted by one or more substituents selected from Group A; R 5 is selected from the group consisting of C 1 -C 10 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, —CH 2 —CH═CH—Z, —(CR 9 R 10 ) m Z; m is an integer from 1 to 6; wherein the alkyl, alkenyl and alkynyl can be substituted with one or more substituents selected from Group A; R 6 is H, —C(O)O(C 1 -C 18 ) alkyl or —C(O)(C 1 -C 18 ) alkyl, wherein one or more carbons of said alkyl may be replaced by a heteroatom selected from O, S and N; R 8 and R 9 are independently selected from H, halo, C 1 -C 6 alkyl; or R 8 and R 9 , together with the carbon to which they are attached, form a 3 to 10 membered cyclic or heterocyclic di-radical; R 10 and R 11 are each independently H or C 1 -C 12 alkyl, or aryl substituted C 1 -C 12 alkyl, or heteroaryl substituted C 1 -C 12 alkyl, wherein one or more carbons of said alkyl are optionally replaced by a heteroatom selected from O, S and N; each Z is independently a 4-10 membered heterocyclic or C 6 -C 10 aryl, wherein said heterocyclic and aryl groups are optionally substituted by one or more substituents selected from Group A; T is absent or selected from the group consisting of: —C(O)—, —C(O)—O—, —CH 2 —, —C(S)—S—, —C(O)—NR 10 —; —S(O) n —, where n is 0, 1, or 2 —S(O) n —O—, wherein n is 0, 1, or 2, —P(O)(OR 10 ) n —, n is 0, 1, or 2, and —S(O) 2 —NR 10 —, R t is selected from the group consisting of: C 1 -C 6 alkyl, C 3 -C 6 alkenyl, C 3 -C 12 cycloalkyl, aryl, heteroaryl, heterocycloalkyl, wherein said alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl groups are optionally substituted by one or more substituents selected from Group A; R w and R x are each independently H, C 1 -C 10 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, C 3 -C 10 cycloalkyl, wherein one or two carbons of said alkyl, cycloalkyl, alkenyl, alkynyl are optionally replaced by one or more heteroatoms selected from O, S and N. and are optionally substituted by one or more substituents selected from Group A.

Claim 4

A compound of formula 2 or pharmaceutically acceptable salts or prodrugs thereof, wherein: R is C 1 -C 10 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, or C 3 -C 10 cycloalkyl, wherein one or two carbons of said alkyl, cycloalkyl, alkenyl, alkynyl are optionally replaced by one or more heteroatoms selected from the group consisting of O, S and N, and are optionally substituted by one or more substituents selected from the group (hereinafter also referred to as “Group A”) consisting of: nitro; N 3 ; CN; C 1 -C 10 alkoxy; C 1 -C 10 alkanoyl; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 10 cycloalkyl; C 3 -C 10 heterocyclic; —C(O)R 10 ; —C(O)OR 10 ; —NR 10 R 11 ; —NHC(O)R 10 ; —NHC(O)NR 10 R 11 ; —S(O) n , wherein n is 0, 1, or 2; —SO 2 R 10 ; —SO 2 NR 10 R 11 ; R 1 and R 4 are independently selected from H, C 1 -C 12 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, (CR 8 R 9 ) m Z, m is an integer from 0 to 6; wherein one or two carbons of said alkyl, alkenyl, alkynyl are optionally replaced by a heteroatom selected from O, S and N, and are optionally substituted by one or more substituents selected from Group A; R 5 is selected from the group consisting of C 1 -C 10 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, —CH 2 —CH═CH—Z, —(CR 9 R 10 ) m Z; m is an integer from 1 to 6; wherein the alkyl, alkenyl and alkynyl can be substituted with one or more substituents selected from Group A; R 6 is H, —C(O)O(C 1 -C 18 ) alkyl or —C(O)(C 1 -C 18 ) alkyl, wherein one or more carbons of said alkyl may be replaced by a heteroatom selected from O, S and N; R 8 and R 9 are independently selected from H, halo, C 1 -C 6 alkyl; or R 8 and R 9 , together with the carbon to which they are attached, form a 3 to 10 membered cyclic or heterocyclic di-radical; R 10 and R 11 are each independently H or C 1 -C 12 alkyl, or aryl substituted C 1 -C 12 alkyl, or heteroaryl substituted C 1 -C 12 alkyl, wherein one or more carbons of said alkyl are optionally replaced by a heteroatom selected from O, S and N; each Z is independently a 4-10 membered heterocyclic or C 6 -C 10 aryl, wherein said heterocyclic and aryl groups are optionally substituted by one or more substituents selected from Group A; T is absent or selected from the group consisting of: —C(O)—, —C(O)—O—, —CH 2 —, —C(S)—S—, —C(O)—NR 10 —; —S(O) n —, where n is 0, 1, or 2 —S(O) n —O—, wherein n is 0, 1, or 2, —P(O)(OR 10 ) n —, n is 0, 1, or 2, and —S(O) 2 —NR 10 —, R t is selected from the group consisting of: C 1 -C 6 alkyl, C 3 -C 6 alkenyl, C 3 -C 12 cycloalkyl, aryl, heteroaryl, heterocycloalkyl, wherein said alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl groups are optionally substituted by one or more substituents selected from Group A; R w and R x are each independently H, C 1 -C 10 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, C 3 -C 10 cycloalkyl, wherein one or two carbons of said alkyl, cycloalkyl, alkenyl, alkynyl are optionally replaced by one or more heteroatoms selected from O, S and N. and are optionally substituted by one or more substituents selected from Group A.

Claim 5

A compound of formula 3 or pharmaceutically acceptable salts or prodrugs thereof, wherein: R is C 1 -C 10 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, or C 3 -C 10 cycloalkyl, wherein one or two carbons of said alkyl, cycloalkyl, alkenyl, and alkynyl are optionally replaced by one or more heteroatoms selected from the group consisting of O, S and N, and are optionally substituted by one or more substituents selected from the group (hereinafter also referred to as “Group A”) consisting of: nitro; N 3 ; CN; C 1 -C 10 alkoxy; C 1 -C 10 alkanoyl; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 10 cycloalkyl; C 3 -C 10 heterocyclic; —C(O)R 10 ; —C(O)OR 10 ; —NR 10 R 11 ; —NHC(O)R 10 ; —NHC(O)NR 10 R 11 ; —S(O) n , wherein n is 0, 1, or 2; —SO 2 R 10 ; —SO 2 NR 10 R 11 ; R 1 is selected from the group consisting of H, C 1 -C 12 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, and —(CR 8 R 9 ) m Z, m is an integer from 0 to 6; wherein one or two carbons of said alkyl, alkenyl, alkynyl are optionally replaced by a heteroatom selected from the group consisting of O, S and N, and are optionally substituted by one or more substituents selected from Group A; R 5 is selected from the group consisting of C 1 -C 10 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, —CH 2 —CH═CH—Z, and —(CR 9 R 10 ) m Z; m is an integer from 1 to 6; wherein the alkyl, alkenyl and alkynyl can be substituted with one or more substituents selected from Group A; R 6 is H, —C(O)O(C 1 -C 18 ) alkyl or —C(O)(C 1 -C 18 ) alkyl, wherein one or more carbons of said alkyl may be replaced by a heteroatom selected from O, S and N; R 8 and R 9 are each independently selected from the group consisting of H, halo, C 1 -C 6 alkyl; or R 8 and R 9 , together with the carbon to which they are attached, form a 3 to 10 membered cyclic or heterocyclic di-radical; R 10 and R 11 are each independently H or C 1 -C 12 alkyl, or aryl substituted C 1 -C 12 alkyl, or heteroaryl substituted C 1 -C 12 alkyl, wherein one or more carbons of said alkyl are optionally replaced by a heteroatom selected from O, S and N; each Z is independently a 4-10 membered heterocyclic or C 6 -C 10 aryl, wherein said heterocyclic and aryl groups are optionally substituted by one or more substituents selected from Group A; T is absent or selected from the group consisting of: —C(O)—, —C(O)—O—, —CH 2 —, —C(S)—S—, —C(O)—NR 10 —; —S(O) n —, where n is 0, 1, or 2, —S(O) n —O—, wherein n is 0, 1, or 2, —P(O)(OR 10 ) n —, n is 0, 1, or 2, and —S(O) 2 —NR 10 —, R t is selected from the group consisting of: C 1 -C 6 alkyl, C 3 -C 6 alkenyl, C 3 -C 12 cycloalkyl, aryl, heteroaryl, and heterocycloalkyl, wherein said alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl groups are optionally substituted by one or more substituents selected from Group A; R w is H, C 1 -C 10 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, or C 3 -C 10 cycloalkyl, wherein one or two carbons of said alkyl, cycloalkyl, alkenyl, alkynyl are optionally replaced by one or more heteroatoms selected from the group consisting of O, S and N, and are optionally substituted by one or more substituents selected from Group A; R z is H, C 1 -C 10 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, or C 3 -C 10 cycloalkyl, wherein one or two carbons of said alkyl, cycloalkyl, alkenyl, and alkynyl are optionally replaced by one or more heteroatoms selected from O, S and N, and are optionally substituted by one or more substituents selected from Group A.

Claim 6

A compound of formula 3 or pharmaceutically acceptable salts or prodrugs thereof, wherein: R is C 1 -C 10 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, or C 3 -C 10 cycloalkyl, wherein one or two carbons of said alkyl, cycloalkyl, alkenyl, and alkynyl are optionally replaced by one or more heteroatoms selected from the group consisting of O, S and N, and are optionally substituted by one or more substituents selected from the group (hereinafter also referred to as “Group A”) consisting of: nitro; N 3 ; CN; C 1 -C 10 alkoxy; C 1 -C 10 alkanoyl; C 1 -C 10 alkyl; C 2 -C 10 alkenyl; C 2 -C 10 alkynyl; C 3 -C 10 cycloalkyl; C 3 -C 10 heterocyclic; —C(O)R 10 ; —C(O)OR 10 ; —NR 10 R 11 ; —NHC(O)R 10 ; —NHC(O)NR 10 R 11 ; —S(O) n , wherein n is 0, 1, or 2; —SO 2 R 10 ; —SO 2 NR 10 R 11 ; R 1 is selected from the group consisting of H, C 1 -C 12 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, and —(CR 8 R 9 ) m Z, m is an integer from 0 to 6; wherein one or two carbons of said alkyl, alkenyl, alkynyl are optionally replaced by a heteroatom selected from the group consisting of O, S and N, and are optionally substituted by one or more substituents selected from Group A; R 5 is selected from the group consisting of C 1 -C 10 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, —CH 2 —CH═CH—Z, and —(CR 9 R 10 ) m Z; m is an integer from 1 to 6; wherein the alkyl, alkenyl and alkynyl can be substituted with one or more substituents selected from Group A; R 6 is H, —C(O)O(C 1 -C 18 ) alkyl or —C(O)(C 1 -C 18 ) alkyl, wherein one or more carbons of said alkyl may be replaced by a heteroatom selected from O, S and N; R 8 and R 9 are each independently selected from the group consisting of H, halo, C 1 -C 6 alkyl; or R 8 and R 9 , together with the carbon to which they are attached, form a 3 to 10 membered cyclic or heterocyclic di-radical; R 10 and R 11 are each independently H or C 1 -C 12 alkyl, or aryl substituted C 1 -C 12 alkyl, or heteroaryl substituted C 1 -C 12 alkyl, wherein one or more carbons of said alkyl are optionally replaced by a heteroatom selected from O, S and N; each Z is independently a 4-10 membered heterocyclic or C 6 -C 10 aryl, wherein said heterocyclic and aryl groups are optionally substituted by one or more substituents selected from Group A; T is absent or selected from the group consisting of: —C(O)—, —C(O)—O—, —CH 2 —, —C(S)—S—, —C(O)—NR 10 —; —S(O) n —, where n is 0, 1, or 2, —S(O) n —O—, wherein n is 0, 1, or 2, —P(O)(OR 10 ) n —, n is 0, 1, or 2, and —S(O) 2 —NR 10 —, R t is selected from the group consisting of: C 1 -C 6 alkyl, C 3 -C 6 alkenyl, C 3 -C 12 cycloalkyl, aryl, heteroaryl, and heterocycloalkyl, wherein said alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, and heterocycloalkyl groups are optionally substituted by one or more substituents selected from Group A; R w is H, C 1 -C 10 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, or C 3 -C 10 cycloalkyl, wherein one or two carbons of said alkyl, cycloalkyl, alkenyl, alkynyl are optionally replaced by one or more heteroatoms selected from the group consisting of O, S and N, and are optionally substituted by one or more substituents selected from Group A; R z is H, C 1 -C 10 alkyl, C 3 -C 10 alkenyl, C 3 -C 10 alkynyl, or C 3 -C 10 cycloalkyl, wherein one or two carbons of said alkyl, cycloalkyl, alkenyl, and alkynyl are optionally replaced by one or more heteroatoms selected from O, S and N, and are optionally substituted by one or more substituents selected from Group A.

Claim 7

The compound of claim 1 wherein R 5 is Me.

Claim 8

The compound of claim 1 wherein R is Et.

Claim 9

The compound of claim 1 wherein R 2 is H and R 3 is H.

Claim 10

The compound of claim 1 wherein T is —C(O)—NH— or wherein —C(O)—O—.

Claim 11

The compound of claim 1 wherein R 1 is (CH 2 ) m Z.

Claim 12

The compound of claim 8 wherein m is 3.

Claim 13

The compound of claim 1 wherein Z is Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl.

Claim 14

The compound of claim 1 wherein R 1 =R 2 =R 3 =R 4 =H, and R 5 is —CH 2 —CH═CH—Z.

Claim 15

The compound of claim 11 wherein Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl.

Claim 16

The compound of claim 2 wherein R 5 is Me.

Claim 17

The compound of claim 2 wherein R is Et.

Claim 18

The compound of claim 2 wherein T is —C(O)—NH— or —C(O)—O—.

Claim 19

The compound of claim 2 wherein R 1 is (CH 2 ) m Z.

Claim 20

The compound of claim 16 wherein m is 3.

Claim 21

The compound of claim 17 wherein Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl.

Claim 22

The compound of claim 2 wherein R 1 =R w =R x =R 4 =H, and R 5 is —CH 2 —CH═CH—Z.

Claim 23

The compound of claim 19 wherein Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl.

Claim 24

The compound of claim 3 wherein R 5 is Me.

Claim 25

The compound of claim 3 wherein R 1 is (CH 2 ) 3 Z.

Claim 26

The compound of claim 22 wherein Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl.

Claim 27

The compound of claim 3 wherein T is —C(O)—NH or —C(O)—O—.

Claim 28

The compound of claim 3 wherein R is Et.

Claim 29

The compound of claim 1 wherein said compound is selected from the group consisting of: Compounds of formula 1, wherein R=Et, R 1 =R 2 =R 3 =R 4 =R 6 =H, and R 5 =(CH 2 )—CH═CH—Z, wherein Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl , 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is absent, R t is H, acetyl, (4-methoxy)benzoyl, methanesulfonyl, Compounds of formula 1, wherein R=Et, R 1 =R 2 =R 3 =R 4 =R 6 =H, and R 5 =(CH 2 )—CH═CH—Z, wherein Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl , quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl , 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —S(O) 2 , R t is —CH═CH 2 , —CH 2 CH 2 N(CH 3 ) 2 , —CH 2 CH 2 S-phenyl, Compounds of formula 1, wherein R=Et, R 1 =R 2 =R 3 =R 4 =R 6 =H, R 5 =(CH 2 )—CH═CH—Z, Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl , quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl , 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —C(O)—NH, R t is (2-nitrophenyl), phenyl, allyl, CH(CH 3 ) 2 , cyclohexyl, Compounds of formula 1, wherein R=Et, R 1 =Me, R 2 =R 3 =R 4 =R 6 =H, R 5 =(CH 2 )—CH═CH—Z, Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl , quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is absent, R t is H, acetyl, (4-methoxy)benzoyl, methanesulfonyl, Compounds of formula 1, wherein R=Et, R 1 =Me, R 2 =R 3 =R 4 =R 6 =H, R 5 =(CH 2 )—CH═CH—Z, Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl , quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —S(O) 2 , R t is —CH═CH 2 , —CH 2 CH 2 N(CH 3 ) 2 , —CH 2 CH 2 S-phenyl, Compounds of formula 1, wherein R=Et, R 1 =Me, R 2 =R 3 =R 4 =R 6 =H, R 5 =(CH 2 )—CH═CH—Z, Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —C(O)—NH, R t is (2-nitrophenyl), phenyl, allyl, CH(CH 3 ) 2 , cyclohexyl, Compounds of formula 1, wherein R=Et, R 4 =Me, R 1 =R 2 =R 3 =R 6 =H, R 5 =(CH 2 )—CH═CH—Z, Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is absent, R t is H, acetyl, (4-methoxy)benzoyl, methanesulfonyl, Compounds of formula 1, wherein R=Et, R 4 =Me, R 1 =R 2 =R 3 =R 6 =H, R 5 =(CH 2 )—CH═CH—Z, Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl , quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —S(O) 2 , R t is —CH═CH 2 , —CH 2 CH 2 N(CH 3 ) 2 , —CH 2 CH 2 S-phenyl, Compounds of formula 1, wherein R=Et, R 4 =Me, R 1 =R 2 =R 3 =R 6 =H, R 5 =(CH 2 )—CH═CH—Z, Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl , quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl , 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3yl-imidazol-1-yl, T is —C(O)—NH, R t is (2-nitrophenyl), phenyl, allyl, CH(CH 3 ) 2 , cyclohexyl, Compounds of formula 1, wherein R=Et, R 2 =R 3 =Me, R 1 =R 4 =R 6 =H, R 5 =(CH 2 )—CH═CH—Z, Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl , quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is absent, R t is H, acetyl, (4-methoxy)benzoyl, methanesulfonyl, Compounds of formula 1, wherein R=Et, R 2 =R 3 =Me, R 1 =R 4 =R 6 =H, R 5 =(CH 2 )—CH═CH—Z, Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl , quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —S(O) 2 , R t is —CH═CH 2 , —CH 2 CH 2 N(CH 3 ) 2 , —CH 2 CH 2 S-phenyl, Compounds of formula 1, wherein R=Et, R 2 =R 3 =Me, R 1 =R 4 =R 6 =H, R 5 =(CH 2 )—CH═CH—Z, Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl , quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, TT is —C(O)—NH, R t is (2-nitrophenyl), phenyl, allyl, CH(CH 3 ) 2 , cyclohexyl, Compounds of formula 1, wherein R=Et, R 1 =R 2 =R 3 =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is absent, R t is acetyl, Compounds of formula 1, wherein R=Et, R 2 =R 3 =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is absent, R t is acetyl, Compounds of formula 1, wherein R=Et, R 2 =R 3 =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is absent, R t is (4-methoxy)benzoyl, Compounds of formula 1, wherein R=Et, R 2 =R 3 =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3yl-imidazol-1-yl, T is absent, R t is methanesulfonyl, Compounds of formula 1, wherein R=Et, R 2 =R 3 =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —S(O) 2 —, R t is —CH═CH 2 , Compounds of formula 1, wherein R=Et, R 2 =R 3 =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —S(O) 2 —, R t is —CH 2 CH 2 N(CH 3 ) 2 , Compounds of formula 1, wherein R=Et, R 2 =R 3 =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —S(O) 2 —, R t is CH 2 CH 2 —S-phenyl, Compounds of formula 1, wherein R=Et, R 2 =R 3 =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —C(O)—NH—, R t is (2-nitrophenyl), Compounds of formula 1, wherein R=Et, R 2 =R 3 =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —C(O)—NH—, R t is phenyl; Compounds of formula 1, wherein R=Et, R 2 =R 3 =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —C(O)NH—, R t is allyl, Compounds of formula 1, wherein R=Et, R 2 =R 3 =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —C(O)—NH—, R t is CH(CH 3 ) 2 , Compounds of formula 1, wherein R=Et, R 2 =R 3 =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —C(O)—NH, R t is cyclohexyl, the pharmaceutically acceptable salts and prodrugs of the foregoing compounds.

Claim 30

The compound of claim 2 wherein said compound is selected from the group consisting of: Compounds of formula 2, wherein R=Et, R 1 =R w =R x =R 4 =R 6 =H, R 5 =(CH 2 )—CH═CH—Z, Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl , quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl , 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is absent, R t is H, acetyl, (4-methoxy)benzoyl, methanesulfonyl, Compounds of formula 2, wherein R=Et, R 1 =R w =R x =R 4 =R 6 =H, R 5 =(CH 2 )—CH═CH—Z, Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl , quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —S(O) 2 , R t is —CH═CH 2 , —CH 2 CH 2 N(CH 3 ) 2 , —CH 2 CH 2 S-phenyl, Compounds of formula 2, wherein R=Et, R 1 =R w =R x =R 4 =R 6 =H, R 5 =(CH 2 )—CH═CH—Z, Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl , quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —C(O)—NH, R t is (2-nitrophenyl), phenyl, allyl, CH(CH 3 ) 2 , cyclohexyl, Compounds of formula 2, wherein R=Et, R w =R x =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is absent, R t is acetyl, Compounds of formula 2, wherein R=Et, R w =R x =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is absent, R t is acetyl, Compounds of formula 2, wherein R=Et, R w =R x =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is absent, R t is (4-methoxy)benzoyl, Compounds of formula 2, wherein R w =R x =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is absent, R t is methanesulfonyl, Compounds of formula 2, wherein R w =R x =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —S(O) 2 —, R t is —CH═CH 2 , Compounds of formula 2, wherein R=Et, R w =R x =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —S(O) 2 —, R t is —CH 2 CH 2 N(CH 3 ) 2 , Compounds of formula 2, wherein R=Et, R w =R x =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —S(O) 2 —, R t is CH 2 CH 2 —S-phenyl, Compounds of formula 2, wherein R=Et, R w =R x =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —C(O)—NH—, R t is (2-nitrophenyl), Compounds of formula 2, wherein R=Et, R w =R x =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —C(O)—NH—, R t is phenyl, Compounds of formula 2, wherein R=Et, R w =R x =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —C(O)NH—, R t is allyl, Compounds of formula 2, wherein R=Et, R w =R x =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —C(O)—NH—, R t is CH(CH 3 ) 2 , Compounds of formula 2, wherein R=Et, R w =R x =R 4 =R 6 =H, R 5 =Me, R 1 =(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —C(O)—NH, R t is cyclohexyl, the pharmaceutically acceptable salts and prodrugs of the foregoing compounds.

Claim 31

The compound of claim 3 , wherein said compound is selected from the group consisting of: Compounds of formula 3, wherein R=Et, R 1 =R w =R 6 =H, R z =Me, R 5 =(—CH 2 )—CH═CH—Z, Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl , quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is absent, R t is H, acetyl, (4-methoxy)benzoyl, methanesulfonyl, Compounds of formula 3, wherein R=Et, R 1 =R w =R 6 =H, R z =Me, R 5 =—(CH 2 )—CH═CH—Z, Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl , quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —S(O) 2 , R t is —CH═CH 2 , —CH 2 CH 2 N(CH 3 ) 2 , —CH 2 CH 2 S-phenyl, Compounds of formula 3, wherein R=Et, R 1 =R w =R 6 =H, R z =Me, R 5 =—(CH 2 )—CH═CH—Z, Z is quinolin-2-yl, quinolin-3-yl, quinolin-4-yl , quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —C(O)—NH, R t is (2-nitrophenyl), phenyl, allyl, —CH(CH 3 ) 2 , cyclohexyl, Compounds of formula 3, wherein R=Et, R w =R 6 =H, R 5 =R z =Me, R 1 =—(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is absent, R t is acetyl, Compounds of formula 3, wherein R=Et, R w =R 6 =H, R 5 =R z =Me, R 1 =—(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is absent, R t is (4-methoxy)benzoyl, Compounds of formula 3, wherein R=Et, R w =R 6 =H, R 5 =R z =Me, R 1 =—(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is absent, R t is methanesulfonyl, Compounds of formula 3, wherein R=Et, R w =R 6 =H, R 5 =R z =Me, R 1 =—(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —S(O) 2 —, R t is —CH═CH 2 , Compounds of formula 3, wherein R=Et, R w =R 6 =H, R 5 =R z =Me, R 1 =—(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —S(O) 2 —, R t is —CH 2 CH 2 N(CH 3 ) 2 , Compounds of formula 3, wherein R=Et, R w =R 6 =H, R 5 =R z =Me, R 1 =—(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —S(O) 2 —, R t is —CH 2 CH 2 —S-phenyl, Compounds of formula 3, wherein R=Et, R w =R 6 =H, R 5 =R z =Me, R 1 =—(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —C(O)—NH—, R t is (2-nitrophenyl), Compounds of formula 3, wherein R=Et, R w =R 6 =H, R 5 =R z =Me, R 1 =—(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —C(O)—NH—, R t is phenyl, Compounds of formula 3, wherein R=Et, R w =R 6 =H, R 5 =R z =Me, R 1 =—(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —C(O)—NH—, R t is allyl, Compounds of formula 3, wherein R=Et, R w =R 6 =H, R 5 =R z =Me, R 1 =—(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —C(O)—NH—, R t is —CH(CH 3 ) 2 ; Compounds of formula 3, wherein R=Et, R w =R 6 =H, R 5 =R z =Me, R 1 =—(CH 2 ) 3 Z, Z is quinolin-4-yl, 4-phenyl-1-imidazol-1-yl, imidazo(4,5-b)pyridin-3-yl, or 4-pyridin-3-yl-imidazol-1-yl, T is —C(O)—NH—, R t is cyclohexyl; the pharmaceutically acceptable salts and prodrugs of the foregoing compounds.

Claim 32

A method of preparing a compound of the formula I in claim 1 : or pharmaceutically acceptable salts thereof, which comprises the steps of treating a compound of the formula 7 with a compound of formula R 2 R 3 C(═O) in the presence of an acid in a solvent and then effecting either alkylation or reductive alkylation.

Claim 33

The method of claim 29 wherein the acid is selected from the group consisting of formic acid, acetic acid, p-toluenesulfonic acid and the solvents are selected from THF, dichloromethane, chloroform.

Claim 34

A pharmaceutical composition for the treatment of a bacterial or protozoa infection in a mammal, fish or bird which comprises a therapeutically effective amount of a compound of claim 1 , and a pharmaceutically acceptable carrier.

Claim 35

A pharmaceutical composition for the treatment of a bacterial or protozoa infection in a mammal, fish or bird which comprises a therapeutically effective amount of a compound of claim 2 , and a pharmaceutically acceptable carrier.

Claim 36

A pharmaceutical composition for the treatment of a bacterial or protozoa infection in a mammal, fish or bird which comprises a therapeutically effective amount of a compound of claim 3 , and a pharmaceutically acceptable carrier.

Claim 37

A method of treating a bacterial or protozoa infection in a mammal, fish, or bird, which comprises administering to said mammal, fish, or bird a therapeutically effective amount of a compound of claim 1 .

Claim 38

A method of treating a bacterial or protozoa infection in a mammal, fish, or bird, which comprises administering to said mammal, fish, or bird a therapeutically effective amount of a compound of claim 2 .

Claim 39

A method of treating a bacterial or protozoa infection in a mammal, fish, or bird, which comprises administering to said mammal, fish, or bird a therapeutically effective amount of a compound of claim 3 .